- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa
Catalyst Biosciences (NASDAQ:CBIO) has announced it has presented updated interim data from its Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA). As quoted in the press release: The data were delivered in an oral presentation at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being …
Catalyst Biosciences (NASDAQ:CBIO) has announced it has presented updated interim data from its Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA).
As quoted in the press release:
The data were delivered in an oral presentation at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held Feb. 6-8, 2019 in Prague.
“The positive data from our clinical trial demonstrate clinical proof-of-concept for MarzAA as a subcutaneous treatment option for individuals with hemophilia A or B with inhibitors,” said Dr. Nassim Usman, chief executive officer of Catalyst. “To date, each participant in the trial has experienced a clinically significant reduction in annualized bleed rate and the percentage of days with bleeding, highlighting the potential for MarzAA as a safe and effective subcutaneous treatment to reduce spontaneous bleed rates and improve the quality of life of affected individuals. We are pleased to announce that we have completed enrollment and look forward to providing topline results in the third quarter of 2019.”
Dr. Howard Levy, chief medical officer of Catalyst, presented the updated results which include data from a total of 11 subjects. Seven subjects have completed dosing in the trial, two are currently dosing, others are completing screening and enrollment is now complete.
To date, for all enrolled patients, the mean annualized bleed rate (ABR) prior to the trial was 19.0 bleeds per year. All subjects who have completed dosing have had clinically significant reductions in ABR and five experienced no bleeds with individualized dosing of either 30 µg/kg MarzAA or 60 µg/kg MarzAA for 50 days. Six subjects had no spontaneous bleeds at their final dose level. The median proportion of days with bleeding for the seven subjects during the pre-study period was 11.0% and this was significantly reduced to a median of 1.0% during the treatment period (p = 0.016). A total of more than 450 days of subcutaneous dosing of MarzAA have been completed with only six localized skin reactions in two subjects, and no anti-drug antibodies to MarzAA have been detected to date.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.